pp-030 Tablets 40 mg
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Autoimmune diseases ( Pemphigus vulgaris (PV) and Rheumatoid arthritis (RA)). Phase I. Oral small-molecule dual inhibitor of JAK3 and Tec family kinases (TFK/BTK) - selectively suppresses T-cell and B-cell activation; first-in-class, expected best-in-class.
Patent / protection status: Several related patents recently filed for autoimmune-kinase inhibitors; PP-030 is within this portfolio.
Manufacturer #7042
A pharmaceutical manufacturer engaged in the research, development, production and global supply of a broad range of pharmaceutical products, including prescription drugs, over-the-counter medicines and biologic therapies in finished dosage forms such as tablets, capsules, ointments, injections and liquids, as well as active pharmaceutical ingredients. The company combines integrated R&D with GMP-compliant manufacturing capabilities and commercial operations to support quality, safety and reliability in its pharmaceutical products for diverse therapeutic needs.